These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2122435)

  • 1. Prodrugs of peptides. 6. Bioreversible derivatives of thyrotropin-releasing hormone (TRH) with increased lipophilicity and resistance to cleavage by the TRH-specific serum enzyme.
    Bundgaard H; Møss J
    Pharm Res; 1990 Sep; 7(9):885-92. PubMed ID: 2122435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prodrugs of peptides. IV: Bioreversible derivatization of the pyroglutamyl group by N-acylation and N-aminomethylation to effect protection against pyroglutamyl aminopeptidase.
    Bundgaard H; Møss J
    J Pharm Sci; 1989 Feb; 78(2):122-6. PubMed ID: 2565975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prodrugs of cimetidine with increased lipophilicity: N-acyloxymethyl and N-alkoxycarbonyl derivatives.
    Buur A; Bundgaard H
    Acta Pharm Nord; 1991; 3(1):51-6. PubMed ID: 1854437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prodrugs of thiabendazole with increased water-solubility.
    Nielsen LS; Bundgaard H; Falch E
    Acta Pharm Nord; 1992; 4(1):43-9. PubMed ID: 1515051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prodrugs of peptides. 19. Protection of the pyroglutamyl residue against pyroglutamyl aminopeptidase by N-acyloxymethylation and other means.
    Møss J; Bundgaard H
    Acta Pharm Nord; 1992; 4(4):301-8. PubMed ID: 1363462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics and pattern of degradation of thyrotropin-releasing hormone (TRH) in human plasma.
    Møss J; Bundgaard H
    Pharm Res; 1990 Jul; 7(7):751-5. PubMed ID: 2118634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prodrug design for brain delivery of small- and medium-sized neuropeptides.
    Prokai-Tatrai K; Prokai L
    Methods Mol Biol; 2011; 789():313-36. PubMed ID: 21922418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prodrugs of peptides. 9. Bioreversible N-alpha-hydroxyalkylation of the peptide bond to effect protection against carboxypeptidase or other proteolytic enzymes.
    Bundgaard H; Rasmussen GJ
    Pharm Res; 1991 Mar; 8(3):313-22. PubMed ID: 2052517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyrotropin-releasing hormone-degrading enzyme in human serum is classified as type II of pyroglutamyl aminopeptidase: influence of thyroid status.
    Yamada M; Mori M
    Proc Soc Exp Biol Med; 1990 Sep; 194(4):346-51. PubMed ID: 1975097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delineation of a particulate thyrotropin-releasing hormone-degrading enzyme in rat brain by the use of specific inhibitors of prolyl endopeptidase and pyroglutamyl peptide hydrolase.
    Friedman TC; Wilk S
    J Neurochem; 1986 Apr; 46(4):1231-9. PubMed ID: 2869108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of a highly specific pyroglutamyl aminopeptidase type-II from the membrane fraction of bovine brain.
    Gallagher SP; O'Connor B
    Int J Biochem Cell Biol; 1998 Jan; 30(1):115-33. PubMed ID: 9597758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating lipophilicity of rohitukine via prodrug approach: Preparation, characterization, and in vitro enzymatic hydrolysis in biorelevant media.
    Kumar V; Bharate SS; Vishwakarma RA
    Eur J Pharm Sci; 2016 Sep; 92():203-11. PubMed ID: 27422078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of novel, centrally-acting thyrotropin-releasing hormone analogues.
    Prokai-Tatrai K; Perjési P; Zharikova AD; Li X; Prokai L
    Bioorg Med Chem Lett; 2002 Aug; 12(16):2171-4. PubMed ID: 12127530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prodrugs of thyrotropin-releasing hormone and related peptides as central nervous system agents.
    Prokai-Tatrai K; Prokai L
    Molecules; 2009 Feb; 14(2):633-54. PubMed ID: 19214153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism-based brain-targeting system for a thyrotropin-releasing hormone analogue.
    Prokai L; Prokai-Tatrai K; Ouyang X; Kim HS; Wu WM; Zharikova A; Bodor N
    J Med Chem; 1999 Nov; 42(22):4563-71. PubMed ID: 10579819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pyridinium-substituted analog of the TRH-like tripeptide pGlu-Glu-Pro-NH2 and its prodrugs as central nervous system agents.
    Prokai-Tatrai K; Teixido M; Nguyen V; Zharikova AD; Prokai L
    Med Chem; 2005 Mar; 1(2):141-52. PubMed ID: 16787309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prodrugs of peptides. 13. Stabilization of peptide amides against alpha-chymotrypsin by the prodrug approach.
    Kahns AH; Bundgaard H
    Pharm Res; 1991 Dec; 8(12):1533-8. PubMed ID: 1808620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal clearance of the thyrotropin-releasing hormone-like peptide pyroglutamyl-glutamyl-prolineamide in humans.
    Klootwijk W; Sleddens-Linkels E; de Boer R; Jansen CA; Autar R; de Herder WW; Boevé ER; Visser TJ; de Greef WJ
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3068-73. PubMed ID: 9284745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A radioimmunoassay for the measurement of pyroglutamyl-histidyl-proline, a proposed thyrotropin releasing hormone metabolite.
    Visser TJ; Klootwijk W; Docter R; Hennemann G
    J Clin Endocrinol Metab; 1975 Apr; 40(4):742-5. PubMed ID: 805158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of brain inactivation of centrally-acting thyrotrophin-releasing hormone (TRH) analogues: a high-performance liquid chromatography study.
    Griffiths EC; McDermott JR; Smith AI
    Regul Pept; 1982 Dec; 5(1):1-11. PubMed ID: 6820170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.